In a cross-over design, pestos enriched with different levels of the microalgae Phaeodactylumtricornutum (2-3-4%) will be tested. The bioavailability of long-chain omega-3 fatty acids, in particular EPA and carotenoids, will be analysed in blood plasma postprandially within two days after a single dose. Pharmacokinetic parameters will be calculated from the measured data. The aim of the study is to gain insight into the bioavailability of selected microalgae constituents and the acceptance of microalgae pesto.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Area under the curve (AUC)- Eicosapentaonic acid
Timeframe: zero to 48 hours, during the whole study
Area under the curve (AUC)- Fucoxanthin
Timeframe: zero to 48 hours, during the whole study
Area under the curve (AUC)- B-Carotin
Timeframe: zero to 48 hours, during the whole study
Maximum Plasma Concentration [Cmax] of Eicosapentaonic acid
Timeframe: zero to 48 hours, during the whole study
Maximum Plasma Concentration [Cmax] of Fucoxanthin
Timeframe: zero to 48 hours, during the whole study
Maximum Plasma Concentration [Cmax] of B-Carotin
Timeframe: zero to 48 hours, during the whole study
Time of the maximum measured plasma concentration (max) of Eicosapentaonic acid
Timeframe: zero to 48 hours, during the whole study
Time of the maximum measured plasma concentration (max) of Fucoxanthin
Timeframe: zero to 48 hours, during the whole study
Time of the maximum measured plasma concentration (max) of B--Carotin
Timeframe: zero to 48 hours, during the whole study